Imaging of fuel mixture fraction oscillations in a driven system using acetone PLIF

Measurements of fuel mixture fraction are made for a jet flame in an acoustic chamber. Acoustic forcing creates a spatially-uniform, temporally-varying pressure field which results in oscillatory behavior in the flame . Forcing is at 22,27, 32, 37, and 55 Hz. To asses the oscillatory behavior, previous work included chemiluminescence, OH PUF, nitric oxide PUF imaging, and fuel mixture fraction measurements by infrared laser absorption. While these results illuminated what was happening to the flame chemistry, they did not provide a complete explanation as to why these things were happening. In this work, the fuel mixture fraction is measured through PUF of acetone, which is introduced into the fuel stream as a marker. This technique enables a high degree of spatial resolution of fuel/air mixture value. Both non-reacting and reacting cases were measured and comparisons are drawn with the results from the previous work. It is found that structure in the mixture fraction oscillations is a major contributor to the magnitude of the flame oscillations

Emerging concepts: linking hypoxic signaling and cancer metabolism

The Joint Keystone Symposia on Cancer and Metabolism and Advances in Hypoxic Signaling: From Bench to Bedside were held in Banff, Alberta, Canada from 12 to 17 February 2012. Drs. Reuben Shaw and David Sabatini organized the Cancer and Metabolism section, and Drs. Volker Haase, Cormac Taylor, Johanna Myllyharju and Paul Schumacker organized the Advances in Hypoxic Signaling section. Accumulating data illustrate that both hypoxia and rewired metabolism influence cancer biology. Indeed, these phenomena are tightly coupled, and a joint meeting was held to foster interdisciplinary interactions and enhance our understanding of these two processes in neoplastic disease. In this report, we highlight the major themes of the conference paying particular attention to areas of intersection between hypoxia and metabolism in cancer. One opening keynote address was delivered by Craig Thompson (Memorial Sloan-Kettering, USA), in which he provided a comprehensive perspective on the current thinking around how altered metabolism supports cancer cell growth and survival, and discussed areas likely to be important for future discovery. In particular, Thompson highlighted the essential roles of glucose and glutamine in cell growth, how glucose- and glutamine-consuming processes are rewired in cancer and how this rewiring facilitates anabolic metabolism. These topics were at the core of many of the metabolism presentations that described in detail how some metabolic alterations contribute to the properties of transformed cells. The other keynote address was delivered by Peter Ratcliffe (University of Oxford, UK), in which he provided a historical perspective on the progress of how signaling events sense oxygen. Mammals have evolved multiple acute and long-term adaptive responses to low oxygen levels (hypoxia). This response prevents a disparity in ATP utilization and produc- tion that would otherwise result in a bioenergetic collapse when oxygen level is low. Multiple effectors have been proposed to mediate the response to hypoxia including prolyl hydroxylases, AMPK, NADPH oxidases and the mitochondrial complex III. Currently, however, the precise mechanism by which oxygen is sensed in various physiological contexts remains unknown. Indeed, this was an active point of debate, with Peter Ratcliffe favoring the prolyl hydroxylase PHD2 as the primary cellular oxygen sensor.Burrough’s Wellcome FundDamon Runyon Cancer Research FoundationLustgarten FoundationSmith family and the Stern famil

Micropropagação de Eucalyptus citriodora e Eucalyptus tereticornis.

Edição dos Anais do Congresso Florestal Brasileiro, 6., 1990, Campos do Jordão

Isobaric multiplet yrast energies and isospin non-conserving forces

The isovector and isotensor energy differences between yrast states of isobaric multiplets in the lower half of the $pf$ region are quantitatively reproduced in a shell model context. The isospin non-conserving nuclear interactions are found to be at least as important as the Coulomb potential. Their isovector and isotensor channels are dominated by J=2 and J=0 pairing terms, respectively. The results are sensitive to the radii of the states, whose evolution along the yrast band can be accurately followed.Comment: 4 pages, 4 figures. Superseeds second part of nucl-th/010404

Neutrino-induced nucleosynthesis of A>64 nuclei: The nu p-process

We present a new nucleosynthesis process, that we denote nu p-process, which occurs in supernovae (and possibly gamma-ray bursts) when strong neutrino fluxes create proton-rich ejecta. In this process, antineutrino absorptions in the proton-rich environment produce neutrons that are immediately captured by neutron-deficient nuclei. This allows for the nucleosynthesis of nuclei with mass numbers A >64. Making this process a possible candidate to explain the origin of the solar abundances of 92,94Mo and 96,98Ru. This process also offers a natural explanation for the large abundance of Sr seen in an hyper-metal-poor star.Comment: 5 pages, 3 figures, submitted to Physical Review Letter

Band termination in the N=Z Odd-Odd Nucleus 46V

High spin states in the odd-odd N=Z nucleus 46V have been identified. At low spin, the T=1 isobaric analogue states of 46Ti are established up to I = 6+. Other high spin states, including the band terminating state, are tentatively assigned to the same T=1 band. The T=0 band built on the low-lying 3+ isomer is observed up to the 1f7/2-shell termination at I=15. Both signatures of a negative parity T=0 band are observed up to the terminating states at I = 16- and I = 17-, respectively. The structure of this band is interpreted as a particle-hole excitation from the 1d3/2 shell. Spherical shell model calculations are found to be in excellent agreement with the experimental results.Comment: 5 pages, 4 figure

The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.

The therapeutic efficacy of gemcitabine, a new nucleoside analogue, was assessed in a variety of well-established human soft tissue sarcoma and ovarian cancer xenografts grown s.c. in nude mice. Tumour lines selected had different histological subtypes, growth rates and sensitivities to conventional cytostatic agents. The three different doses and schedules designed on the basis of a mean weight loss between 5% and 15% were i.p. injections of daily 3.5 mg kg-1 x 4, every 3 days 120 mg kg-1 x 4, and weekly 240 mg kg-1 x 2, which ultimately resulted in 19%, 10% and 4% toxic deaths, respectively. The weekly schedule induced > or = 50% growth inhibition in 2/4 soft tissue sarcoma and 4/6 ovarian cancer lines, while in three ovarian cancer lines > or = 75% growth inhibition was obtained. The anti-tumour effects of gemcitabine appeared to be similar or even better than previous data with conventional drugs tested in the same tumour lines. In comparison with the every 3 days schedule, the weekly and the daily schedule were less effective in 5/7 and 3/3 tumour lines (P < 0.001), respectively. In another experiment in three human tumour lines selected for their differential sensitivity to gemcitabine, weekly injections of 240 mg kg-1 x 6 did not result in a significant increase in the percentages of growth inhibition when compared to lower doses of 120 mg kg-1 or 60 mg kg-1 in the same schedule. However, the 240 mg kg-1 weekly x 6 schedule showed superior effects in 2/3 tumour lines in comparison with the same dose given every 2 weeks x 3 (P < 0.05). The preclinical activity of gemcitabine suggests that the drug can induce responses in soft tissue sarcoma and ovarian cancer patients. Our results further indicate that clinical trials of gemcitabine in solid tumour types should be designed on the basis of a schedule rather than a dose dependence